Relationship of Serum Nesfatin-1 and Insulin-Like Growth Factor-1 Levels with Adverse Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome

What Was Tested

This observational study looks at IGF-1 LR3.

To investigate the relationship between serum nesfatin-1 and insulin-like growth factor-1 (IGF-1) levels and adverse pregnancy outcomes (APOs) in patients with polycystic ovary syndrome (PCOS).

Why It Was Studied

Polycystic ovary syndrome, Nesfatin-1, Insulin-like growth factor-1, Adverse pregnancy outcome.

Who Took Part

According to the abstract, 120 women were involved.

By PubMed's age tags, the people studied were adults, women only.

Place and Duration of the Study: The study was performed from June 2021 to 2023 in the General Gynaecology section at the Maternity & Child Care Center of Qinhuangdao, Hebei, China.

A total of 120 pregnant women with PCOS were divided into the control and study groups.

How the Study Was Run

The control group consisted of 70 pregnant women who successfully delivered healthy newborns, whereas the study group included 50 pregnant women who experienced APOs.

The serum nesfatin-1 and IGF-1 levels in both groups were measured upon admission.

The potential influencing factors of APOs in pregnant women with PCOS and the predictive value of serum nesfatin-1 and IGF-1 for APOs were analysed.

What Was Measured

Polycystic ovary syndrome, Nesfatin-1, Insulin-like growth factor-1, Adverse pregnancy outcome.

Topics PubMed links to this paper include Nucleobindins, Polycystic Ovary Syndrome, Insulin-Like Growth Factor I, Pregnancy Outcome, China, Case-Control Studies and Pregnancy Complications.

What This Means in Plain Language

This is an observational study of IGF-1 LR3 in 120 women.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Journal of the College of Physicians and Surgeons--Pakistan : JCPSP), a journal based in Pakistan.

More context: the IGF-1 LR3 compound page, all human trials.